ALA on Glycemic Control in T2DM Participants

• Conditions: Type 2 Diabetes Mellitus

• Registration Number: NCT02701894
• Lead Sponsor: Unity Health Toronto

Brief Summary

With the emerging worldwide epidemic of type 2 diabetes, dietary recommendations to improve diabetes management have been emphasized in the scientific community. Particular attention has been drawn to various benefits of replacing saturated fatty acids with unsaturated fatty acids. Alpha-linolenic acid, the only omega-3 fatty acid that is from plant sources, has been suggested by animal and cell studies to play a beneficial role in regulating blood glucose levels. However, human studies have been more inconsistent with their findings. The focus of this project is to investigate the evidence in the context of ALA and blood glucose parameters in participants with type 2 diabetes by conducting a systematic review and meta-analysis of randomized controlled trials.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-12
• Status Verified: 2016-03
• Primary Completion: 2016-03
• Study Completion: 2016-03
• Study First Submitted: 2016-03-02
• Study First Submitted QC: 2016-03-02
• Last Update Submitted: 2016-03-02
• Study First Posted: 2016-03-08
• Last Update Posted: 2016-03-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Controlled, randomized, clinical trials
• Trials greater than one month
• Focusing on ALA and T2DM participants
• Viable endpoint data

Read More

Exclusion Criteria

• Non-human studies
• Non-random treatment allocation
• Less than 1 month
• Lack of suitable control
• Lack of endpoint data

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HbA1c	1 month

Secondary Outcome Measures

Name	Time	Method
Glycated Albumin	1 month
HOMA- IR	1 month
Fructosamine	1 month
Fasting Blood Glucose	1 month
Fasting Blood Insulin	1 month